Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free WINT Stock Alerts

Windtree Therapeutics (WINT) Competitors

Windtree Therapeutics logo
$0.0002 0.00 (0.00%)
As of 08/14/2026 11:19 AM Eastern
Compare

WINT vs. LIPO, ALVOW, APLMW, ARAV, and BIAFW

Should you buy Windtree Therapeutics stock or one of its competitors? Windtree Therapeutics's main competitors and comparable companies include Lipella Pharmaceuticals (LIPO), Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), and bioAffinity Technologies (BIAFW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Windtree Therapeutics compare to Lipella Pharmaceuticals?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Windtree Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Windtree Therapeutics' return on equity of -207.34% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Windtree Therapeutics N/A -207.34%-50.19%

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Windtree Therapeutics Neutral

Windtree Therapeutics has lower revenue, but higher earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.00-$5.02M-$2.42N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lipella Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

Summary

Windtree Therapeutics beats Lipella Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Windtree Therapeutics compare to Alvotech?

Windtree Therapeutics (NASDAQ:WINT) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Alvotech has higher revenue and earnings than Windtree Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Alvotech$559.42MN/AN/AN/AN/A

29.3% of Windtree Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Alvotech had 2 more articles in the media than Windtree Therapeutics. MarketBeat recorded 2 mentions for Alvotech and 0 mentions for Windtree Therapeutics. Alvotech's average media sentiment score of 0.93 beat Windtree Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Windtree Therapeutics Neutral
Alvotech Positive

Alvotech's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Alvotech N/A N/A N/A

Summary

Alvotech beats Windtree Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Windtree Therapeutics compare to Apollomics?

Windtree Therapeutics (NASDAQ:WINT) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Apollomics has higher revenue and earnings than Windtree Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Apollomics$8.50MN/AN/AN/AN/A

In the previous week, Apollomics had 3 more articles in the media than Windtree Therapeutics. MarketBeat recorded 3 mentions for Apollomics and 0 mentions for Windtree Therapeutics. Apollomics' average media sentiment score of 0.29 beat Windtree Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the news media.

Company Overall Sentiment
Windtree Therapeutics Neutral
Apollomics Neutral

Apollomics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Apollomics N/A N/A N/A

29.3% of Windtree Therapeutics shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Apollomics beats Windtree Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Windtree Therapeutics compare to Aravive?

Windtree Therapeutics (NASDAQ:WINT) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Aravive Neutral

Aravive's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Aravive N/A N/A N/A

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 35.8% of Aravive shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aravive is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
AraviveN/AN/AN/A-$0.90N/A

Summary

Aravive beats Windtree Therapeutics on 5 of the 6 factors compared between the two stocks.

How does Windtree Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and Windtree Therapeutics (NASDAQ:WINT) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, bioAffinity Technologies had 3 more articles in the media than Windtree Therapeutics. MarketBeat recorded 3 mentions for bioAffinity Technologies and 0 mentions for Windtree Therapeutics. bioAffinity Technologies' average media sentiment score of 0.73 beat Windtree Therapeutics' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company Overall Sentiment
bioAffinity Technologies Positive
Windtree Therapeutics Neutral

bioAffinity Technologies' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Windtree Therapeutics N/A -207.34%-50.19%

bioAffinity Technologies has higher revenue and earnings than Windtree Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

29.3% of Windtree Therapeutics shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

bioAffinity Technologies beats Windtree Therapeutics on 5 of the 7 factors compared between the two stocks.

Get Windtree Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WINT vs. The Competition

Export
MetricWindtree TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9K$3.72B$7.05B$13.10B
Dividend YieldN/A3.70%2.57%10.45%
P/E Ratio0.0010.67269.0825.28
Price / SalesN/A1,306.50604.1191.83
Price / CashN/A102.8870.4850.90
Price / Book0.0016.7812.916.24
Net Income-$1.79M-$13.32M$3.45B$347.60M
7 Day PerformanceN/A1.77%1.11%1.06%
1 Month PerformanceN/A1.16%1.33%0.81%
1 Year PerformanceN/A54.22%62.44%20.90%

Windtree Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WINT
Windtree Therapeutics
N/A$0.00
flat		N/A-100.0%$9KN/AN/A30
LIPO
Lipella Pharmaceuticals
N/A$0.00
flat		N/AN/A$1K$536.36KN/A4
ALVOW
Alvotech
N/A$0.15
flat		N/A-85.4%$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.02
+11.3%		N/A-24.4%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:WINT) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel